. 2014 Apr 30;12(5):2408–2421. doi: 10.3390/md12052408

Table 4.

Physiological and pharmacological effects of APS12-2 and APS3 in vitro.

Measured Parameters		APS12-2 *		APS3 **
Measured Parameters		Effect	IC₅₀	Effect	IC₅₀
Skeletal muscle contraction	Nerve-evoked stimulation	Inhibition	0.74 μM	Inhibition	20.3 μM
Skeletal muscle contraction	Direct stimulation	No effect up to 2.72 μM	N/A	No effect up to 20.55 μM	N/A
Pharmacological effect	atropine	No effect up to 80 μM	N/A	No effect up to 80 μM	N/A
	neostigmine	No effect up to 1 μM	N/A	No effect up to 1 μM	N/A
	3,4-DAP	Stops muscle contraction blockade (300 μM)	N/A	Stops muscle contraction blockade (300 μM)	N/A
Effect on	RP	No effect up to 3.40 μM	N/A	No effect up to 68.49 μM	N/A
	MEPP	Amplitude decrease, MEPP disappear above 0.68 μM	N/A	Amplitude decrease, MEPP disappear above 6.85 μM	N/A
	EPP	Amplitude decrease	0.36 μM	Amplitude decrease	7.28 μM
nAChRs inhibition		Inhibition	0.0005 μM	Inhibition	0.19 μM
Effect on coronary rings ***		Contraction (4.1–13.6 μM)	N/A	No effect up to 137 μM	N/A

N/A, Not applicable; 3,4-DAP, 3,4-diaminopyridine; RP, resting membrane potential; MEPP, miniature endplate potential; EPP, endplate potential; nAChRs, nicotinic acetylcholine receptors; * [49]; ** [42]; *** [57].